Codexis Inc (CDXS)vsMerck & Company Inc (MRK)
CDXS
Codexis Inc
$2.56
-8.57%
HEALTHCARE · Cap: $254.51M
MRK
Merck & Company Inc
$120.79
-1.42%
HEALTHCARE · Cap: $285.64B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 84119% more annual revenue ($65.77B vs $78.09M). MRK leads profitability with a 13.6% profit margin vs -41.0%. MRK appears more attractively valued with a PEG of 5.36. MRK earns a higher WallStSmart Score of 50/100 (D+).
CDXS
Avoid34
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+83.5%
Fair Value
$7.19
Current Price
$2.56
$4.63 discount
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 102.1% year-over-year
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Expensive relative to growth rate
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CDXS
The strongest argument for CDXS centers on Revenue Growth. Revenue growth of 102.1% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : CDXS
The primary concerns for CDXS are EPS Growth, Market Cap, Debt/Equity. Debt-to-equity of 1.69 is elevated, increasing financial risk.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
CDXS profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
CDXS carries more volatility with a beta of 2.48 — expect wider price swings.
CDXS is growing revenue faster at 102.1% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 34/100). CDXS offers better value entry with a 83.5% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Codexis Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Codexis, Inc. discovers, develops and sells biocatalysts. The company is headquartered in Redwood City, California.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?